NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer

Small cell lung cancer (SCLC) is a high-grade malignancy, and treatment strategies have not changed for decades. In this study, we searched for novel targets for antibody-drug conjugate (ADC) therapy for SCLC. We identified transmembrane proteins overexpressed specifically in SCLC with little or no...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Yotsumoto, Takuma, Maemura, Keita, Watanabe, Kousuke, Amano, Yosuke, Matsumoto, Yoko, Zokumasu, Koichi, Ando, Takahiro, Kawakami, Masanori, Kage, Hidenori, Nakajima, Jun, Yatomi, Yutaka, Nagase, Takahide, Takai, Daiya
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2020
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7533074/
https://ncbi.nlm.nih.gov/pubmed/33062195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27718
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak